I agree that this site is using cookies. You can find further informations here.
X
Ogura, Michinori
144  results:
Search for persons X
?
1

Analyzing the risk factors for disease progression within 2..:

Watanabe, Takashi ; Matsuno, Yoshihiro ; Wakabayashi, Masashi...
Hematological Oncology.  42 (2024)  3 - p. , 2024
Link: https://doi.org/10.1002/..
 
?
2

R‐CHOP treatment for patients with advanced follicular lymp..:

Watanabe, Takashi ; Tobinai, Kensei ; Wakabayashi, Masaki...
British Journal of Haematology.  204 (2023)  3 - p. 849-860 , 2023
Link: https://doi.org/10.1111/..
 
?
3

Long‐term follow‐up after R‐High CHOP/CHASER/LEED with Auto..:

Ogura, Michinori ; Yamamoto, Kazuhito ; Morishima, Yasuo...
Cancer Science.  114 (2023)  8 - p. 3461-3465 , 2023
Link: https://doi.org/10.1111/..
 
?
4

Bendamustine plus rituximab in Japanese patients with relap..:

Murayama, Kayoko ; Kiguchi, Toru ; Izutsu, Koji...
Annals of Hematology.  101 (2022)  5 - p. 979-989 , 2022
Link: https://doi.org/10.1007/..
 
?
5

Efficacy and Safety of CT-P10 Versus Rituximab in Untreated..:

Kwak, Larry W. ; Sancho, Juan-Manuel ; Cho, Seok-Goo...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  2 - p. 89-97 , 2022
Link: https://doi.org/10.1016/..
 
?
6

A phase I/II study of 10-min dosing of bendamustine hydroch..:

Ishizawa, Kenichi ; Yokoyama, Masahiro ; Kato, Harumi...
Cancer Chemotherapy and Pharmacology.  90 (2022)  1 - p. 83-95 , 2022
Link: https://doi.org/10.1007/..
 
?
7

A multicenter, phase II study of full-dose THP-COP therapy ..:

Ohmachi, Ken ; Ogura, Michinori ; Kagami, Yoshitoyo...
Journal of Clinical and Experimental Hematopathology.  62 (2022)  4 - p. 202-207 , 2022
Link: https://doi.org/10.3960/..
 
?
8

A multicenter, phase II study of R-THP-COP therapy for elde..:

Ohnishi, Kazunori ; Ohmachi, Ken ; Ando, Kiyoshi...
Journal of Clinical and Experimental Hematopathology.  61 (2021)  3 - p. 162-167 , 2021
Link: https://doi.org/10.3960/..
 
?
9

Long-term efficacy and safety of CT-P10 or rituximab in unt..:

Buske, Christian ; Jurczak, Wojciech ; Sancho, Juan-Manuel...
Blood Advances.  5 (2021)  17 - p. 3354-3361 , 2021
Link: https://doi.org/10.1182/..
 
?
10

Correction to: Safety profile of brentuximab vedotin in Jap..:

Izutsu, Koji ; Ogura, Michinori ; Tobinai, Kensei...
International Journal of Hematology.  113 (2021)  4 - p. 611-611 , 2021
Link: https://doi.org/10.1007/..
 
?
11

Safety profile of brentuximab vedotin in Japanese patients ..:

Izutsu, Koji ; Ogura, Michinori ; Tobinai, Kensei...
International Journal of Hematology.  113 (2021)  3 - p. 404-412 , 2021
Link: https://doi.org/10.1007/..
 
?
12

Clinical characteristics of patients with B-cell lymphoma e..:

Kinoshita, Tomohiro ; Watanabe, Takashi ; Itoh, Kuniaki...
Journal of Clinical and Experimental Hematopathology.  61 (2021)  1 - p. 35-41 , 2021
Link: https://doi.org/10.3960/..
 
?
13

A randomized phase 2/3 study of R-CHOP vs CHOP combined wit..:

Ohmachi, Ken ; Kinoshita, Tomohiro ; Tobinai, Kensei...
Blood Advances.  5 (2021)  4 - p. 984-993 , 2021
Link: https://doi.org/10.1182/..
 
?
14

Phase I studies of darinaparsin in patients with relapsed o..:

Ogura, Michinori ; Kim, Won-Seog ; Uchida, Toshiki...
Japanese Journal of Clinical Oncology.  51 (2020)  2 - p. 218-227 , 2020
Link: https://doi.org/10.1093/..
 
?
15

A phase 3 randomized study (HOMER) of ofatumumab vs rituxim..:

Maloney, David G. ; Ogura, Michinori ; Fukuhara, Noriko...
Blood Advances.  4 (2020)  16 - p. 3886-3893 , 2020
Link: https://doi.org/10.1182/..
 
1-15